M657L
Category 4 — Stable Fold, Function DisruptedConflictingLumenal · predictedσ-1 candidateEditorialMethionine → Leucine at position 657 in lumenal domain. ClinVar Conflicting. AlphaMissense 0.15 (below threshold) — AM under-call. DynaMut2 ΔΔG +0.29. pLDDT 52 borderline.
Interactive 3D Structure
Bond changes · DynaMut2 interaction analysis
| Interaction type | Wild-type partner | Mutant partner | Status |
|---|---|---|---|
| Hydrogen bond | S654 | S654 | Preserved |
| Hydrogen bond | V659 | V659 | Preserved |
| Hydrogen bond | — | E830 | Gained |
| Polar contact | S654 | S654 | Preserved |
| Polar contact | E655 | E655 | Preserved |
| Polar contact | V659 | V659 | Preserved |
| Carbonyl | E655 | E655 | Preserved |
| Van der Waals | S654 | S654 | Preserved |
| Van der Waals | E655 | E655 | Preserved |
| Hydrophobic | — | V659 | Gained |
Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.
Computational Predictions
Clinical Evidence
Observed at very low frequency in gnomAD.
Structural Context
Position 657 at lumenal domain start. Neighbors: LYS658 (2.5 Å), GLY656 (2.5 Å), SER654 (3.8 Å). Borderline confidence region.
M657L loses methionine-specific chemistry (oxidative regulation, S-mediated contacts). AM 0.15 under-call; Conflicting evidence.
Druggability Assessment
Mechanism: lost methionine-specific chemistry. Therapeutic: wet-lab validation recommended.
Why this matters
Feed this card to Wolfram Intelligence
Download the M657L PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.